CJC-1295 isn't found on pharmacy shelves in Dadus or virtually any local market — it's a research compound available through a dedicated online market. What this means for Dadus researchers is that physical proximity is irrelevant compared to your ability to verify analytical documentation — and those verification methods are within reach of all serious researchers. What reliably differentiates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. This guide gives Dadus researchers the methodology to evaluate CJC-1295 vendors systematically and source research-grade CJC-1295 with confidence.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Dadus comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy CJC-1295 — A Researcher's Guide
The most consistent path to quality CJC-1295 is community research first — peptide forums aggregate real purchasing experience that are more reliable than search results. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with negligible secondary peaks representing impurities — purity should be at or above 98%. The combination of peer feedback and direct document verification is the most reliable sourcing approach — community feedback surfaces recurring issues no single purchase reveals, and vice versa. For Dadus researchers making a first CJC-1295 purchase: work through this evaluation framework first, order conservatively at first, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Dadus
COA-verified · International tracking · Research grade
All use of CJC-1295 in Dadus or anywhere constitutes research use — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Bacterial endotoxin contamination is the greatest safety hazard unique to this class of compound — verify endotoxin testing is documented in your batch COA before any injectable research application. Protocol documentation — documenting product details, dates, and administration precisely — is a fundamental research principle that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
